To read the full story, subscribe or sign in.

China Grand Pharma advances radionuclide ITM-11 to phase III

March 25, 2024

China’s National Medical Products Administration has cleared China Grand Pharmaceutical and Healthcare Holdings Ltd. to advance radiopharmaceutical agent ITM-11 (177Lu-edotreotide) to phase III trials in gastroenteropancreatic-neuroendocrine tumors

BioWorld Clinical Medical technology Regulatory Cancer Gastrointestinal Asia-Pacific China NMPA

Today's news in brief

BioWorld

BioWorld briefs for May 7, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 5, 2026

Rendering of a key measles protein targeted by neutralizing human antibodies

First measles treatment advances as vaccination rates drop

BioWorld

Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...

The epidermal growth factor receptor in the inactive (left) and active (right) form.

Cytospire raises £61M series A to target EGFR in solid tumors

BioWorld

Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...

Bio Korea 2026: US policy risks shift to execution framework

BioWorld

Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...